Zepbound Now Available Through Hims & Hers

Follow Drugslib on

Medically reviewed by Drugs.com.

By I. Edwards HealthDay Reporter

WEDNESDAY, April 2, 2025 -- The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

The company said Tuesday it now provides access to Zepbound, a brand-name version of the drug tirzepatide, as well as to generic liraglutide.

Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance, some patients may pay as little as $25, according to a report published by The Wall Street Journal.

Other medications for weight loss on the Hims & Hers platform include Ozempic and Wegovy, priced at $1,799 and $1,999 per month, respectively.

“We’ve now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform,” Hims & Hers said.

Lilly said it has no official connection with Hims & Hers.

Hims & Hers said it plans to keep expanding its offerings to help people find the treatment that works best for them.

“All of this is part of our long-term commitment to build the most comprehensive and personalized digital health platform for weight loss and beyond,” Hims & Hers noted.

The company’s weight-loss business is growing fast. Hims & Hers expects at least $725 million in revenue from its weight-loss services alone in 2025.

In 2023, the company brought in nearly $1.5 billion from more than 2 million customers.

In the fourth quarter of 2023, the company launched an oral weight-loss program, reaching $100 million in revenue in just seven months.

It added GLP-1 drugs like tirzepatide in mid-2024, which brought in about $225 million more that year.

In February, CEO Andrew Dudum said 200,000 new customers joined the platform for weight-loss help over the past year.

Chief Financial Officer Yemi Okupe added, “consumers are very motivated to lose weight and have a holistic platform to do so.”

Sources

  • The Wall Street Journal, April 1, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-04-03 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords